2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4694 Beyond traditional thrombophilia: Venous thromboembolism risk in compound heterozygous sickle cell disease

Abraham Attah, MD, Nneka Nwachukwu, MD2, Jhonsley Frederic, MD3, Ross M. Fasano I, MD4, Morgan McLemore, MD5, Fuad El Rassi, MD6
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
5 Emory University School of Medicine, Atlanta, Georgia, United States
6 Emory University School of Medicine, Atlanta, Georgia, United States

Introduction: Venous thromboembolism (VTE) is a recognized complication of sickle cell disease (SCD), arising from a hypercoagulable state generated by chronic hemolysis, inflammation, endothelial activation, and rheologic abnormality; each potentiated by vaso-occlusive crisis (VOC). Although previous studies have identified risk factors for VTE in SCD, these findings have been derived predominantly from individuals with hemoglobin (Hb) SS genotype. The epidemiology and disease-related risk factors among individuals with compound heterozygous genotypes remain poorly characterized, highlighting an unmet knowledge gap that can affect clinical management and preventive measures in this population. This study assessed VTE prevalence and associated risk factors in adults with sickle cell-hemoglobin C disease (HbSC) and sickle cell-β⁺ thalassemia (HbSβ⁺).

Methods: This retrospective, IRB approved, cross-sectional study reviewed adults (≥18 years) with HbSC or HbSβ⁺receiving care at the Georgia Comprehensive Sickle Cell Center, Grady Memorial Hospital, Atlanta, GA, from 2015 to 2025. Patients were classified by the presence or absence of radiographically confirmed VTE. Electronic medical records were reviewed for demographics, SCD-specific comorbidities, VTE risk factors, hormonal contraceptive use and annualized healthcare utilization. Events were classified as provoked, unprovoked, or undetermined and pulmonary embolism (PE). Comparison was made using Fisher's exact and Mann-Whitney U tests, with logistic regression adjusting for prespecified covariates (age, sex, body mass index [BMI], smoking, genotype, acute chest syndrome [ACS], splenectomy, central venous access, hydroxyurea [HU] use, hospitalization frequency). Significance was set at p ≤ 0.05. Results are reported in percentages, odds ratio (OR), adjusted odds ratio (aOR) with 95% confidence interval (CI) or median with interquartile range (IQR).

Results: Of 482 patients analyzed (64.1% HbSC, 35.9% HbSβ⁺), median age was 36 years (IQR 29-49), 56.8% were female, and 99.6% were African American. Venous thromboembolism occurred in 23.2%. Etiology was documented for 86 events, of which 90.7% were provoked (36.0% line-associated, 33.7% VOC, 5.8% COVID-19, 5.8% prolonged immobilization, 2.3% surgery and 1.2% JAK2+ essential thrombocytosis) and 9.3% unprovoked.

Central venous access had the strongest association with VTE (OR 10.50, 5.81-18.96). Having ≥1 SCD complication raised the odds (OR 2.82, 1.68-4.74), increasing further at ≥3 concurrent complications (OR 5.32, 2.26-12.50); individual associations included ACS (OR 3.32, 2.12-5.18), splenectomy (OR 2.84, 1.59-5.06), retinopathy (OR 2.49, 1.39-4.46), and AVN (OR 1.76, 1.14-2.72). Healthcare utilization was likewise associated, with ≥2 hospitalizations (OR 3.76, 2.31-6.10) or ≥4 acute care visits (OR 4.22, 2.62-6.78) annually. Obesity was associated with VTE only at BMI ≥40 (OR 3.98, 1.98-8.03), not BMI ≥30 (OR 1.51, 0.98-2.35). No association was seen for either genotype, HU, hormonal contraceptive or smoking.

Independent predictors of VTE were central venous access (aOR 6.20, 3.02-12.74), ACS (aOR 3.62, 2.08-6.33), BMI ≥40 (aOR 3.18, 1.22-8.30), ≥2 hospitalizations annually (aOR 2.89, 1.59-5.27), splenectomy (aOR 2.30, 1.11-4.77) and age (aOR 1.03/y, 1.02-1.05). Among patients with VTE, 40.5% had a recurrent event and recurrence was associated only with PE as the index event (OR 3.71, 1.44-9.59).

Conclusion: Nearly one in four adults with HbSC or HbSβ⁺ disease had VTE, with recurrence in 40.5% of those affected, challenging the view of compound heterozygous SCD as low risk for thrombosis. VTE prevalence rose with SCD complication burden and healthcare utilization, and ACS and splenectomy remained independently associated after adjustment, raising the possibility that SCD severity, rather than genotype, is the principal driver of thrombotic risk. Severe obesity (BMI ≥40) was likewise independent, identifying weight management as a modifiable target, while central venous access showed the strongest association overall, warranting prospective evaluation of thromboprophylaxis in patients with chronic catheters. Findings are limited by the retrospective single-center design, likely enrichment for severe disease, and cross-sectional structure precluding causal inference. These results offer an initial view of an increasingly important SCD subpopulation and identify targets for management guidelines.

Jhonsley Frederic, MD: No relevant conflicts of interest to declare.